Literature DB >> 34941182

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study: Erratum.

.   

Abstract

Entities:  

Year:  2021        PMID: 34941182      PMCID: PMC8702238          DOI: 10.1097/MD.0000000000028405

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


× No keyword cloud information.
In the article, “Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study”[ which published in Volume 100, Issue 44 of Medicine¸ the values in the OR column of Table 2 were rounded. The correct table appears below and have been corrected in the published article. Insert Table 2 Fisher's exact test ABCB1 = Adenosine Triphosphate Binding Cassette B1, CI = Confidence Interval, COMT = Catechol-O-Methyltransferase, DRD2 = Dopamine Receptor D2, FAAH = Fatty Acid Amide Hydrolase, GIRK2 = G-protein regulated Inward Rectifier potassium channel 2, OPRD1 = Opioid δ receptor 1, OPRK1 = Opioid κ Receptor 1, OPRM1 = Opioid μ Receptor 1, OR = Odds Ratio
rs1799971 Alt allele freq: 0.494 A > G ORRM1rs2234918 Alt allele freq: 0.79 C > T OPRD1
AlleleA/AA/G + G/GOR95% CI P G/GA/A + A/GOR95% CI P C/CC/T + T/TOR95% CI P T/TC/C + C/TOR95% CI P
n = 22n = 66n = 21n = 67n = 5n = 83n = 56n = 32
Somnolence6 (27.3%)13 (19.7%)1.50.5 to 4.7.550 (0.0%)19 (28.4%)00 to 0.6.0051 (20.0%)18 (21.7%)0.90.1 to 8.61.0010 (17.9%)9 (28.1%)0.60.2 to 1.6.29
Nausea1 (4.5%)13 (19.7%)0.20.02 to 1.6.175 (23.8%)9 (13.4%)2.00.6 to 6.9.310 (0.0%)14 (16.9%)00 to 6.01.0012 (21.4%)2 (6.3%)4.10.9 to 19.6.07
Constipation10 (45.5%)24 (36.4%)1.50.6 to 3.9.469 (42.9%)25 (37.3%)1.30.5 to 3.4.491 (20.0%)33 (39.8%)0.40.04 to 3.5.6423 (41.1%)11 (34.4%)1.30.5 to 3.3.65
Delirium1 (4.5%)9 (13.6%)0.30.04 to 2.5.443 (14.2%)7 (10.4%)1.40.3 to 6.1.700 (0.0%)10 (12.0%)00 to 9.21.006 (10.7%)4 (12.5%)0.80.2 to 3.21.00
Urinary retention0 (0.0%)3 (4.5%)00 to 7.61.002 (9.5%)1 (1.5%)7.00.6 to 80.8.140 (0.0%)3 (3.6%)00 to 46.41.002 (3.6%)1 (3.1%)1.20.1 to 13.21.00
Pruritus4 (18.1%)8 (12.1%)1.60.5 to 6.0.492 (9.5%)10 (14.9%)0.60.1 to 3.00.720 (0.0%)12 (14.5%)00 to 7.31.008 (14.3%)4 (12.5%)1.20.3 to 4.21.00

Fisher's exact test

ABCB1 = Adenosine Triphosphate Binding Cassette B1, CI = Confidence Interval, COMT = Catechol-O-Methyltransferase, DRD2 = Dopamine Receptor D2, FAAH = Fatty Acid Amide Hydrolase, GIRK2 = G-protein regulated Inward Rectifier potassium channel 2, OPRD1 = Opioid δ receptor 1, OPRK1 = Opioid κ Receptor 1, OPRM1 = Opioid μ Receptor 1, OR = Odds Ratio

  1 in total

1.  Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.

Authors:  Rei Tanaka; Junya Sato; Hiroshi Ishikawa; Tetsu Sato; Michihiro Shino; Yasuhisa Ohde; Tetsumi Sato; Keita Mori; Akifumi Notsu; Sumiko Ohnami; Maki Mizuguchi; Takeshi Nagashima; Ken Yamaguchi
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  1 in total
  1 in total

1.  Diagnostic value of double low-dose targeted perfusion CT imaging for the diagnosis of invasive and preinvasive pulmonary ground-glass nodules: systematic review and meta-analysis.

Authors:  Yu Wu; Bao Chen; Li Su; Xiang Qiu; Xiaoyan Hu; Wenbo Li
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.